FDA warns of transdermal drug patches - MPR
Links shared publicly online about this topic.
- 2,212total visits
FDA warns of transdermal drug patches - MPR
empr.com —
View full resource at empr.com
Tags: Emergency, Burn, Drug, Imaging Tests, Magnetic Resonance Imaging, Healthcare, Aluminum, FDA
Most Recently Shared on March 5, 2009 at 7:31 pm By:
FDA warns of transdermal drug patches: The FDA has notified health care professionals and patients that certain .. http://snipurl.com/d63y0
Novartis files suit against Watson over generic Exelon
news-medical.net — “Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rivastigmine transdermal system patches, 4.6 mg/24 hr and 9.5 mg/24 hr.” View full resource at news-medical.net
Most Recently Shared on November 11, 2011 at 5:17 am By:
Parkinson's Disease: Novartis files suit against Watson over generic Exelon: Watson Pharmaceuticals, Inc. today ... http://t.co/ldd6pUdi
Medical News: Sumatripan Patch Fails to Win FDA Nod - in Neurology, Migraines from MedPage Today
medpagetoday.com — “The FDA has turned down a transdermal patch formulation of the migraine drug sumatriptan, citing safety, chemistry, and manufacturing issues, its developer said.” View full resource at medpagetoday.com
Most Recently Shared on September 1, 2011 at 9:18 pm By:
Roger D. Jones, PhD PhD, Doctor, Health Executive, and Health Social Media
Medical News: Sumatripan Patch Fails to Win FDA Nod - http://t.co/NONb90z from @medpagetoday #health #medicine
Medical News: Sumatripan Patch Fails to Win FDA Nod - in Neurology, Migraines from MedPage Today
medpagetoday.com — “The FDA has turned down a transdermal patch formulation of the migraine drug sumatriptan, citing safety, chemistry, and manufacturing issues, its developer said.” View full resource at medpagetoday.com
Most Recently Shared on August 31, 2011 at 1:44 pm By:
Sumatripan Patch Fails to Win FDA Nod http://t.co/lQOPPdq
Medical News: Sumatripan Patch Fails to Win FDA Nod - in Neurology, Migraines from MedPage Today
medpagetoday.com — “The FDA has turned down a transdermal patch formulation of the migraine drug sumatriptan, citing safety, chemistry, and manufacturing issues, its developer said.” View full resource at medpagetoday.com
Most Recently Shared on August 31, 2011 at 1:41 pm By:
FDA turns down sumatriptan patch Zelrix for migraine: http://t.co/Y0w1dUb
Drug patches pose overlooked danger to kids - TODAY Health - TODAY.com
today.msnbc.msn.com — “An 8-month-old Maine boy who overdosed on a grandparent's used medication patch is prompting patient safety experts to warn caregivers about dangers to kids posed by growing numbers and types of transdermal medications. ” View full resource at today.msnbc.msn.com
Most Recently Shared on August 12, 2011 at 2:33 pm By:
Mary Sue McAslan Pharmacist, PharmD, and Doctor
Dangerous drug patches pose overlooked risk to kids: http://t.co/NuwtHMA via @todayshow
Drug patches pose overlooked danger to kids - Health - Kids and parenting - msnbc.com
msnbc.msn.com — “An 8-month-old Maine boy who overdosed on a grandparent's used medication patch is prompting patient safety experts to warn caregivers about dangers to kids posed by growing numbers and types of transdermal medications. ” View full resource at msnbc.msn.com
Most Recently Shared on August 11, 2011 at 12:52 pm By:
msnbc.com - Health Health News
Drug patches pose overlooked danger to kids http://on.msnbc.com/qVHDD0
Covidien Receives FDA Approval For Fentanyl Transdermal System Patch - QualityPoint Technologies
qualitypointtech.net — “Covidien (NYSE: COV), a leading global provider of healthcare products, announced that Mallinckrodt Inc., a Covidien company, has received U.S. Food and Drug Administration (FDA) approval of its Abbreviated New Drug Application (ANDA) for its Fentanyl Transdermal System (FTS) patch. Covidien is the largest supplier of controlled pain medications in the United States based on number of prescriptions. Covidien's FTS is a generic alternative to the branded DURAGESIC® patch...” View full resource at qualitypointtech.net
Most Recently Shared on February 13, 2011 at 6:35 pm By:
Covidien Receives FDA Approval For Fentanyl Transdermal System Patch: Covidien (NYSE: COV), a leading global provi... http://bit.ly/gdiTY4
Covidien Receives FDA Approval For Fentanyl Transdermal System Patch
medicalnewstoday.com — “Covidien (NYSE: COV), a leading global provider of healthcare products, announced that Mallinckrodt Inc., a Covidien company, has received U.S. Food and Drug Administration (FDA) approval of its A” View full resource at medicalnewstoday.com
Most Recently Shared on February 13, 2011 at 1:05 pm By:
MNT Pain News Health News and Pain Management
Covidien Receives FDA Approval For Fentanyl Transdermal System Patch http://mnt.to/3R6H #pain
Teikoku Pharma USA Announces FDA Accepts Aricept(R) Patch (Donepezil Transdermal System) NDA For Review
medicalnewstoday.com — “Teikoku Pharma USA, Inc., an international specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA)” View full resource at medicalnewstoday.com
Most Recently Shared on September 21, 2010 at 12:05 pm By:
MNT Drug Approvals Health News
Teikoku Pharma USA Announces FDA Accepts Aricept(R) Patch (Donepezil Transdermal System) NDA For Review http://mnt.to/3K3F #regulatory
FDA Accepts Aricept, Patch (Donepezil Transdermal System) NDA For Review - QualityPoint Technologies
qualitypointtech.net — “Teikoku Pharma USA, Inc., an international specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for a new weekly transdermal patch of Aricept,, a leading medication for the treatment of Alzheimer's disease. The company developed the weekly Aricept(r) patch based on a license agreement executed between Teikoku Pharma USA, Inc. and Eisai Co., Ltd. (Eisai) in February 2009. The acceptance of the NDA indic” View full resource at qualitypointtech.net
Most Recently Shared on September 18, 2010 at 8:13 pm By:
FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA For Review: Teikoku Pharma USA, Inc., an internat... http://bit.ly/cojyJC
FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA For Review
medicalnewstoday.com — “Teikoku Pharma USA, Inc., an international specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for a” View full resource at medicalnewstoday.com
Most Recently Shared on September 18, 2010 at 2:05 pm By:
FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA For Review http://mnt.to/3JZZ #stress
FDA accepts to review Aricept NDA for Alzheimer's disease
news-medical.net — “Teikoku Pharma USA, Inc., an international specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for a new weekly transdermal patch of Aricept, a leading medication for the treatment of Alzheimer's disease.” View full resource at news-medical.net
Most Recently Shared on September 18, 2010 at 4:29 am By:
FDA accepts to review Aricept NDA for Alzheimer's disease: Teikoku Pharma USA, Inc., an international specialty ph... http://bit.ly/9cGJqS
FDA accepts NDA for Aricept Patch for Alzheimer's disease (AD) - ONA
oncologynurseadvisor.com — “Eisai announced that the FDA has accepted for filing the New Drug Application (NDA) submitted for Aricept Patch (donepezil transdermal system) for the treatment of mild, moderate and severe stages of Alzheimer's disease (AD).” View full resource at oncologynurseadvisor.com
Most Recently Shared on September 17, 2010 at 2:45 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
FDA accepts NDA for Aricept Patch for Alzheimer's disease (AD) http://goo.gl/fb/8E9Zg
FDA Accepts Aricept Patch (Donepezil Transdermal System) NDA for Review - Drugs.com MedNews
drugs.com — “Sep 17, 2010 - Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for the Aricep” View full resource at drugs.com
Most Recently Shared on September 17, 2010 at 1:14 pm By:
Drugs and Devices OW OW Health
FDA Accepts Aricept Patch (Donepezil Transdermal System) NDA for Review: WOODCLIFF LAKE, N.J.--(BUSINESS WIRE... http://bit.ly/9SfEfq #drug
Vyteris announces phase II trial results of transdermal patch for female infertility - Clinical Trials
pharmabiz.com — “Vyteris, Inc., developer of the first FDA-approved active transdermal patch and a leader in alternative drug delivery technology, announced positive results from a phase II clinical trial evaluating the safety and efficacy” View full resource at pharmabiz.com
Most Recently Shared on August 13, 2010 at 10:48 am By:
Vyteris announces phase II trial results of transdermal patch for female infertility: Vyteris, Inc., developer of ... http://bit.ly/br3w2X
Advertisement
